Results 11 to 20 of about 18,028 (178)

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. [PDF]

open access: bronzeBlood, 2017
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that most commonly affects adults and is driven by a high frequency of mutations in BRAF, MAP2K1, and kinases promoting MAPK signaling.
Papo M   +22 more
europepmc   +3 more sources

Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. [PDF]

open access: bronzeMol Cancer Ther, 2019
The BRAFV600E mutation and BRAF inhibitor responsiveness characterize ∼50% of patients with the non-Langerhans cell histiocytosis (non-LCH) Erdheim–Chester disease (ECD). We interrogated the non-LCH molecular landscape [ECD, n = 35; Rosai–Dorfman disease
Janku F   +9 more
europepmc   +4 more sources

A rare cutaneous lesion in the neonatal period: The non-Langerhans cell histiocytosis

open access: goldMarmara Medical Journal, 2020
The non-Langerhans cell histiocytosis (non-LCH) is a group of diseases characterized by cutaneous involvement in the neonatal period. The non-LCH affects less than 1 in 200,000 children born each year.
Adnan Barutçu   +3 more
openalex   +3 more sources

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis

open access: goldBlood Advances, 2023
Key Points • MAPK alterations are a hallmark of ECD and RDD.• The MEK inhibitor trametinib is active in non-LCHs, including those without BRAF V600E mutations.
Ashley Aaroe   +12 more
openalex   +2 more sources

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

open access: bronzeBlood, 2019
Background: Activation of the MAPK pathway through BRAF mutations or other molecular alterations is a hallmark of the non-Lagerhans cell histiocytosis (non-LCH) such Erdheim-Chester disease (ECD) or Rosai-Dorfman disease (RDD).
Filip Janků   +5 more
openalex   +2 more sources

Synovial Non-langerhans Cell Histiocytosis of the Shoulder: A Case Report and Review of the Literature. [PDF]

open access: yesJ Orthop Case Rep, 2020
Introduction: Histiocytoses are rare disorders and most orthopedic surgeons are unfamiliar with this diagnosis. We report a case of synovial non-Langerhans cell histiocytosis (LCH) located in the shoulder, which has not been reported in the literature ...
Huri G   +3 more
europepmc   +2 more sources

A RARE CASE OF PULMONARY NON-LANGERHANS CELL HISTIOCYTOSIS [PDF]

open access: bronze, 2020
Victoria González   +3 more
openalex   +2 more sources

Isolated Bone Marrow Non–Langerhans Cell Histiocytosis Preceding RUNX1-Mutated Acute Myeloid Leukemia: Case Report and Literature Review [PDF]

open access: bronzeAmerican Journal of Clinical Pathology, 2019
OBJECTIVES The prevalence of concomitant myeloid neoplasms was recently reported to be unexpectedly high among adults without non-Langerhans cell histiocytosis (non-LCH); however, the coexistence of non-LCH with RUNX1 genetic aberration has not been ...
Areej Al Mugairi   +5 more
openalex   +2 more sources

Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon-α

open access: bronze, 2005
Erdheim-Chester disease is a rare non-Langerhans histiocytosis with multisystem involvement. To date, there is no standard treatment for this disorder, and more than half of the patients succumb within 3 years.
Fadi Braiteh   +3 more
openalex   +2 more sources

Renovascular Hypertension: Unraveling a Case of Mixed Histiocytosis

open access: yesAnnals of Internal Medicine: Clinical Cases, 2023
Renovascular hypertension is a cause of secondary hypertension. Atherosclerotic renal artery stenosis and fibromuscular dysplasia are the main causes, but other rare entities can involve the renal arteries.
Pedro Marques   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy